Emtherapro
Emtherapro is dedicated to advancing the diagnosis and treatment of neurodegenerative diseases through pioneering science, data, and insights. They empower biotech, life sciences, and pharmaceutical companies to develop effective diagnostics and therapies using a comprehensive next-generation precision medicine approach, focusing on proteomics, drug discovery, and clinical trials. Their mission is to create new and effective diagnostics and therapies for neurodegenerative diseases by leveraging advanced omics technologies and clinical expertise.
Industries
Nr. of Employees
small (1-50)
Emtherapro
123 Neurodegenerative Ave, Science City, SC 12345
Products
Median-polish batch correction R implementation
Documented R function implementing a median-polish–based batch correction and normalization method for multiplexed proteomics datasets; code is publicly available for download.
Median-polish batch correction R implementation
Documented R function implementing a median-polish–based batch correction and normalization method for multiplexed proteomics datasets; code is publicly available for download.
Services
Production of large-scale quantitative proteomic datasets from brain tissue, cerebrospinal fluid and blood with integration to transcriptomic and genomic data for cohort-level studies.
Discovery, verification and validation of protein biomarkers for risk profiling, diagnosis, monitoring, prognosis and pharmacodynamic readouts using quantitative proteomics and cross-cohort analyses.
Proteomics-driven target identification and mechanism-of-action analysis to support therapeutic target nomination and inform preclinical prioritization.
Support for participant screening, pharmacodynamic monitoring, drug engagement and dosage optimization, and companion-diagnostic development to enable biomarker-driven clinical trials.
Analytical services applying machine learning, artificial intelligence and systems-biology approaches to extract actionable signatures from complex proteomic and multi-omic datasets.
Curation of reference biofluid and tissue cohorts and disease-specific standards to accelerate biomarker discovery and validation workflows.
Production of large-scale quantitative proteomic datasets from brain tissue, cerebrospinal fluid and blood with integration to transcriptomic and genomic data for cohort-level studies.
Discovery, verification and validation of protein biomarkers for risk profiling, diagnosis, monitoring, prognosis and pharmacodynamic readouts using quantitative proteomics and cross-cohort analyses.
Proteomics-driven target identification and mechanism-of-action analysis to support therapeutic target nomination and inform preclinical prioritization.
Support for participant screening, pharmacodynamic monitoring, drug engagement and dosage optimization, and companion-diagnostic development to enable biomarker-driven clinical trials.
Analytical services applying machine learning, artificial intelligence and systems-biology approaches to extract actionable signatures from complex proteomic and multi-omic datasets.
Curation of reference biofluid and tissue cohorts and disease-specific standards to accelerate biomarker discovery and validation workflows.
Expertise Areas
- Precision proteomics for neurodegenerative disease
- Proteomic biomarker discovery and validation in biofluids and tissues
- Large-scale quantitative mass spectrometry workflows and QC
- Protein co-expression network analysis and module detection
Key Technologies
- Isobaric-label multiplexed quantitative proteomics
- High-resolution liquid chromatography–tandem mass spectrometry (LC–MS/MS)
- MS3-based reporter-ion quantification
- High-pH reversed-phase peptide fractionation
News & Updates
A comprehensive proteomic analysis of over 1,000 brain tissues revealing novel AD-related protein modules and insights into disease biology.
Identification of CSF biomarkers associated with AD through integrated proteomics analysis.
Discovery of early energy metabolism changes in AD brain and CSF linked to microglia and astrocyte activation.
A comprehensive proteomic analysis of over 1,000 brain tissues revealing novel AD-related protein modules and insights into disease biology.
Identification of CSF biomarkers associated with AD through integrated proteomics analysis.
Discovery of early energy metabolism changes in AD brain and CSF linked to microglia and astrocyte activation.